4DQSAR
Bluelighter
- Joined
- Feb 3, 2025
- Messages
- 5,441
While I have sampled a couple of dozen dopamagenic compounds, in every case I found them to be dysphoric.
In the case of MDPV, a SIMPLER homologue was covered i.e. pyrovalerone. It's less potent but it's also far less destructive. Higher potency is not axiomatically BETTER.
So be it pyrovalerone or pyrophenidone (a bioisostere of pyrovalerone), both share the important advantage of being less selectively dopamagenic and with shorter durations of action AND safer metabolisms.
I do find it funny when RC manufacturers assume that animal models provide reasonable insights into likely subjective activity in man. In my experience, EXAMPLE 1 in most patents it the most desirable product. Rarely the most potent, but the one considered best.
In the case of MDPV, a SIMPLER homologue was covered i.e. pyrovalerone. It's less potent but it's also far less destructive. Higher potency is not axiomatically BETTER.
So be it pyrovalerone or pyrophenidone (a bioisostere of pyrovalerone), both share the important advantage of being less selectively dopamagenic and with shorter durations of action AND safer metabolisms.
I do find it funny when RC manufacturers assume that animal models provide reasonable insights into likely subjective activity in man. In my experience, EXAMPLE 1 in most patents it the most desirable product. Rarely the most potent, but the one considered best.

